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A B S T R A C T
Objectives: To compare four UK models evaluating the cost-effectiveness of interventions
in coronary heart disease (CHD), exploring the relative importance of structure and inputs in
accounting for differences, and the scope for consensus on structure and data.
Methods: We compared published cost-effectiveness results (incremental cost, quality-
adjusted life year, and cost-effectiveness ratio) of three models conforming to the National
Institute for Health and Clinical Excellence guidelines dealing with three interventions
(statins, percutaneous coronary intervention, and clopidogrel) with a model developed in
Southampton. Comparisons were made using three separate stages: 1) comparison of pub-
lished results; 2) comparison of the results using the same data inputs wherever possible;
and 3) an in-depth exploration of reasons for differences and the potential for consensus.
Results: Although published results differed by up to 73% (for statins), standardization of
inputs (stage 2) narrowed these gaps. Greater understanding of the reasons for differences
was achieved, but a consensus on preferred values for all data inputs was not reached.
Conclusions: We found that published guidance on methods was important to reduce varia-
tion in importantmodel inputs. Although the comparison ofmodels did not lead to consensus
for allmodel inputs, it provided a better understanding of the reasons for these differences, and
enhanced the transparency and credibility of all models. Similar comparisons would be aided
by fuller publication of models, perhaps through detailed web appendices.
Copyright © 2011, International Society for Pharmacoeconomics and Outcomes Research(ISPOR). Published by Elsevier Inc.
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54 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0ians, clinicians, and health economists. There may also be a
ange of models that evaluate the same technology but use
ifferent methods and produce different results.
One way to increase the perceived credibility of a model is
o test and demonstrate its validity. Four methods of valida-
ion have been suggested and these have been summarized by
hilips et al. [1]. First, internal consistency implies that the
ractical model should behave as the theoretical model pre-
icts, and that it is “debugged.” Second, external consistency
mplies that the model should demonstrate face validity; that
he outputs of a model are consistent with our knowledge of a
isease or intervention. Third, between-model consistency
mplies that different independent models addressing the
ame question should give similar results. Fourth, predictive
alidity involves testing the results of a model against observ-
ble data or a prospective study to ascertain that the results
re similar.
The fourth test of validity could be thought of as a “gold
tandard test” andwould be themost credible evidence for the
eracity of a model. If the results of a model matched real-
orld observations then we might have greater confidence.
owever, this is not generally possible because these models
re often used to combine evidence from multiple sources, to
xtrapolate the results of a short-term clinical trial to the life-
pan of patients or to generalize results to “real-world” set-
ings. In these situations, data are unlikely to be available to
ormally assess the predictive validity ofmodels and checking
or between-model consistency may be the most feasible way
f validating amodel. If structure, inputs, and results are sim-
lar between models it implies there is general agreement on
ow tomodel a particular intervention or disease area; hence,
t may mean that there is a clear preference for methods and
ata inputs. If there are disagreements between models in
ata inputs or structure then checking between-model consis-
ency can highlight the important differences in terms of al-
ering results. Effort can then be concentrated on those differ-
nces which may lead to either consensus over the use of
xisting data or more effort to generate better data. It is in-
reasingly common to identify sets of alternative models that
ddress a similar decision problem or disease area. For exam-
le, in a recent assessment of the cost-effectiveness of antivi-
als for the treatment of influenza, a total of 22 separate stud-
es were identified (including 7 from a UK perspective) [2].The
xistence of alternative models provides an important oppor-
unity to explore similarities and differences betweenmodels.
Differences between models can be due to differences in
arameter values, methods, and structures. These are similar
o the sources of uncertainty in models [3]. Parameter differ-
nces could include state transition probabilities and the
uality-adjusted life year (QALY) losses associated with those
tates. Data on the costs of being in particular states and the
osts of transition between those states could also be included
n this category as could the data and assumptions used to
haracterize uncertainty in a probabilistic model. Many po-
ential sources of data exist, particularly for a disease which is
oth common andwell researched. Different data setsmay be
articularly suited for answering specific questions.
Differences between models may also be attributed to
ethodological differences including: the methods used to derive utility values, the perspective of the analysis (either
HS or a societal perspective), and the discount rate used.
ome of these will be reduced by closer adherence to guide-
ines [1] and the National Institute for Health and Clinical Ex-
ellence (NICE) reference case [4]. Differences may also arise
ue to structural issues, including the modeling approach
sed (e.g., Markov, decision tree, or discrete event simulation).
hey may also be because of differences in the questions ad-
ressed or the health states included in models. Models may
over a single technology ormaymodel a disease or population.
Some differences between models may be legitimate be-
ause two models set up to answer different questions may
ave different structures. Also, some differences may occur
ecause analysts have correctly followed different sets of
uidelines applicable to separate jurisdictions, or the analyses
ave been conducted at different times. Other differences
ay arise because there is no obvious “best” approach; these
ay require a need for clarification and future research to
btain more reliable or appropriate sources of data. Identify-
ng these differenceswould be a useful outcome of any checks
f between-model consistency.
To examine the feasibility and usefulness of a check of
etween-model consistency, we compared the Southampton
HD treatment model with three previously published mod-
ls. The research question of the Southampton treatment
odelwas “What are the relative cost-effectiveness ratios of a
ide range of commonly used treatments for coronary heart
isease for a UK population?” This involved using data on the
linical effectiveness and cost of a number of coronary care
nterventions and meant that comparisons could be made
ith many other CHD models, providing they addressed any
f the interventions covered by the Southampton model. The
outhampton treatment model was developed as part of a
tudy that modeled CHD [5,6].
Comparator models were selected from the literature, re-
tricting comparisons to models specific to the UK and con-
orming to the NICE reference case. Furthermore, we re-
tricted comparisons to models covering one of the
nterventions evaluated by the Southampton treatment
odel. This meant that each model focused on NHS practice
nd followed similar guidelines for economic modeling. This
ncreased the comparability of the models as there were a
umber of characteristics thatwould be shared; two examples
re the use of a cost per QALY approach and a health service
erspective. It alsomeant that therewere differences between
odels published at different times.
One of the comparatormodelswas developed at the School
f Health andRelated Research at theUniversity of Sheffield to
ook at the cost-effectiveness of statins (School of Health and
elated Research [ScHARR]-statins model) [7]. Specifically,
his model was constructed to answer the question: “at what
evel of CHD/cardiovascular disease (CVD) risk are statins cost
ffective in the United Kingdom?” The other two comparator
odels were developed at the University of York. The York
ercutaneous coronary intervention (York-PCI) model [8] was
esigned to “explore the cost effectiveness of thrombolysis
ompared to primary angioplasty in acute myocardial infarc-
ion (MI) patients.” The last model (York-clopidogrel) [9] was
esigned to “explore the cost-effectiveness of clopidogrel plus
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55V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0tandard care compared to standard care alone in the treat-
ent of non-ST-segment elevated acute coronary syndrome.”
he structure of both York models was derived from earlier
ork on a glycoprotein IIb/IIIa model [10]. A summary of the
ore structure of each model is provided (Table 1), and each
odel adhered closely to published guidelines for cost-effec-
ivenessmodels [1]. In addition to Table 1, detailedmodel infor-
ation for the Southampton treatment model is available as a
Table 1 – Summary descriptions of all models compared.
Model
(Publication year)
Southampton treatment (2008*) ScH
Study population CHD population CHD co
Intervention A range of interventions were
modeled
Statins
treat
Treatment
duration
Varied depending upon intervention Lifetim
Model time horizon Lifetime Lifetim
Treatment effect on
mortality
Relative risks. Statin  0.72; primary
PCI  0.68 changed to 0.469,
thrombolysis  0.69, clopidogrel 
0.8
Males s
prev
risk
Discount rate 3.50% 6% cos
Model type Markov Markov
No. of states Modeled 8 states: well, unstable
angina, angina, post-MI (first year),
post-MI subsequent years, heart
failure, CHD death, non-CHD
death.
Transition probabilities reported
in web appendix at:
10.1016/j.jval.2010.10.009
Modele
even
angi
angi
trans
attac
deat
(post
split
CHD
CVD
Tran
prob
repo
p90 o
Baseline cohort Population by age and sex Age 55
Base case results ICER 
Intervention costs
(Per year)
Clopidogrel  £460; aspirin  £9;
statin  £148; thrombolysis 
£316; primary angioplasty 
£3377
Statins
Price year† 2005/6 2004
Utility‡ Post-MI (1st year)  0.68; post-MI
subsequent years  0.72; unstable
angina  0.77; angina  0.81; heart
failure  0.66
Utility
angi
unst
0.770
trans
even
0.629
CHD, coronary heart disease; CVD, cardiovascular disease; ICER, incr
neous coronary intervention; QALY, quality-adjusted life year; ScHAR
* The Southampton treatment model has not previously been publis
† No adjustments have been made to present the model results usin
‡ Utility values derived from health state valuations from patients v
derived from assumption.eb appendix found at: 10.1016/j.jval.2010.10.009. This article tresents the findings of an assessment of model validity using
hilips’ third method of between-model consistency. This exer-
ise had three aims. First, to compare the estimated cost-effec-
iveness of interventions for CHD obtained from different mod-
ls. Second, to identify those differences in inputs and structural
omponents which were most important to the outputs calcu-
ated, and to explore the relative importance of structure and
nputs. Finally, to identify areas where there was agreement be-
-statin
7)
York-PCI (2007) York-clopidogrel
(2004)
First acute MI Unstable angina or non-
ST elevated MI
pared to no Thrombolysis compared to
primary angioplasty
Clopidogrel compared to
standard therapy
6 months 1 year
Lifetime Lifetime
dary
n. Relative
92
Long-term odds ratio  0.7 Long-term relative risk
0.71 (0.60 to 0.84)
% benefits 3.50% 6% costs, 1.5% benefits
Decision tree plus Markov Decision tree plus
Markov
states:
, MI, stable
stable
D death,
ischemic
oke, CVD
er death,
non-fatal,
history of
story of
ies
n Table 52,
A report
Modeled 4 states: dead,
non-fatal MI, non-fatal
stroke, alive with
ischemic heart disease.
Transition probabilities
reported in Table 2,
p1240 of article
Modeled 4 states: well,
MI (first cycle), post-
MI, dead. Transition
probabilities reported
in Table 27, p41 of
HTA report
cohort Age 61, male cohort Age 64–68, mixed cohort
00/QALY ICER  £9241/QALY ICER  £6078/QALY
17 Thrombolysis  £600;
primary angioplasty 
£4097
Clopidogrel  £464;
aspirin  £3.47
2004 2001/2
e: stable
0.808;
ngina 
0.760;
ischemic
, stroke 
MI first year  0.683; MI
subsequent years 
0.718; non-disabling
stroke  0.740; disabling
stroke  0.380;
combined stroke 
0.612. Valuations from
patients
Well  0.8, MI (first
cycle)  0.8, post-MI 
0.8, dead  0
tal cost-effectiveness ratio; MI, myocardial infarction; PCI, percuta-
hool of Health and Related Research.
The year here refers to when analysis was completed.
mmon price year.
using societal norms except for values from Main et al. which wereARR
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56 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0ures and inputs. This process would also identify areas where
herewas disagreement, and in these caseswe aimed to explore
he reason for these differences.
ethods
omparisons between models were made in three stages. In
ll cases changes were made to the Southampton treatment
odel only. Stage 1 involved a comparison of the main pub-
ished (base-case) results. The only change applied at this
tage was to alter the Southampton treatmentmodel to take a
ohort approach (a cohort of 1000 men, 55–64 years old) to
nable a comparisonwith an equivalent cohort approach used
n the three alternative models. Stage 2 involved further
hanges to the Southampton treatment model. These com-
rised structural changes, such as removing particular health
tates (e.g., heart failure in the statin comparison), as well as
hanging relevant data inputs to match the approaches used
n the alternativemodels. The Southampton treatmentmodel
as thus standardized to reflect the other models in terms of
iscount rate, utilities, costs, effectiveness, mortality rates,
revalence, and assumptions. The effects of these changes on
osts, life years, QALYs, and incremental cost-effectiveness
atios (ICER) were recorded. After all feasible changes were
ade, the final outputs were compared.
Stage 3 aimed to reach understanding of the reasons for
he differences between models and for the choices made
ith respect to model structure and data sources using a
eries of one-way sensitivity analyses to evaluate the effect
f each change on the model results. These sensitivity anal-
ses involved changing the parameter values for a range of
ata inputs in the Southampton model to the values used in
he comparator model. These changes were carried out se-
uentially, with each parameter returned to its original
alue before the value assigned to the next parameter was
ltered. This demonstrated the effect of each change and its
elative importance in reducing the differences between the
outhampton treatment model and the comparator model
or estimates of cost, QALYs, and cost per QALY. Stage 3 also
nvolved collaboration with experts from all three compar-
tor models. After the desk-based comparisons we ex-
hanged documents and held three teleconferences be-
ween all three centers to explore reasons for differences in
Table 2 – Overview results of comparison (mean per patien
Model
Statins comparison Southampton-statin, stage 1 result
Southampton-statin, stage 2 results
ScHARR-statin
PCI comparison Southampton-PCI, stage 1 results
Southampton-PCI, stage 2 results
York-PCI
Clopidogrel comparison Southampton-clopidogrel, stage 1 results
Southampton-clopidogrel, stage 2 results
York-clopidogrel
PCI, percutaneous coronary intervention; QALY, quality-adjusted lifeesults. Some additional two-way teleconferences were also weld. An initial draft paper was prepared by the Southamp-
on group, and then shared and iteratively developed with
ork and Sheffield colleagues.
esults
he results of the analyses are shown in Table 2. This table
rovides the results for each comparator model. Also pro-
ided are the stage 1 results, which give the unadjusted
outhampton treatment model results for each of the three
omparisons. For statins, the incremental cost-effective-
ess ratio predicted by the Southampton treatment model
as very different (73% lower) than the value predicted by
he ScHARR-statin model. The difference was primarily in
he cost, with the incremental cost in the Southampton
odel one-quarter of that in the ScHARR model. This was
artly but not exclusively due to the lower yearly cost for
tatins in the Southampton model (£148 compared to £316).
or the PCI comparison the Southampton-treatment model
roduced a higher ICER, being 33% greater than the value for
he York-PCI model. However, this difference hides the ex-
ent of the difference in estimated incremental costs and
ALYs, which were 70% and 78% lower, respectively. For the
lopidogrel comparison the stage 1 results gave a higher
CER, being 63% higher, but the estimated costs and QALYs
ere much lower, being 72% and 83% lower, respectively.
he absolute values of the incremental costs and QALYs
ere comparatively small in both clopidogrel models.
Table 2 also shows the results for the stage 2 analysis and
ives the effects of including parameter values from the com-
arator models in the Southampton model results. For the
tatin comparison, after stage 2, the ICERs were much closer;
he Southampton treatment model was 29% lower. This con-
ergence was caused by an increase in the estimated incre-
ental costs in the Southamptonmodel. The difference in the
ncremental QALYswidened at this stage. For the PCI compar-
son, the stage 2 changes had only aminor impact on the ICER
ecause the value changed to 25% greater than the York
odel. However, the values for both incremental costs and
ncremental QALYs were still much lower for the Southamp-
on treatment model. For the clopidogrel comparison incre-
ental costs, QALYs and the ICER were all closely matched
fter stage 2; the ICER for the Southampton treatment model
ncremental cost (£) Incremental QALYs ICER (£/QALY)
1900 0.505 3760
3430 0.350 9800
7860 0.565 13,900
800 0.065 12,250
1020 0.088 11,590
2680 0.290 9240
130 0.013 9930
480 0.058 8210
470 0.077 6080
; ScHARR, School of Health and Related Research.t).
Ias 35% higher. This difference was caused by differences in
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57V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0ncremental QALYs because the two estimates of incremental
osts were almost identical after stage 2.
As part of stage 3, a series of one-way sensitivity analysis
howed the effect on the baseline incremental costs, QALYs,
nd ICER of each of the changes made (Table 3). For the statin
odel a comparison of a number of changes wasmade (effec-
iveness of the intervention, statin cost, utility values, and
iscount rates). Taken together these had large effects on both
he incremental cost and incremental QALYs (increases of
5% and 41%, respectively). However, the percentage effect on
he ICERwas lower (increase by 17%). The change that had the
ingle largest effect on the ICERwas removing the heart failure
tate. Age-adjusted utility values and changing the rates of
HD-related mortality in health states, particularly for stable
ngina, also had an important impact. For the PCI comparison,
he most important changes made to the ICER were to the
osts of the intervention. Changing the prevalence had large
ffects on both the incremental costs and incremental QALYs;
owever, because these were of the same sign andmagnitude
increase of 26%), they had a negligible effect on the ICER. For
he clopidogrel comparison, changes in the discount rate pro-
uced the largest effect on the results.
iscussion
e found that the predicted ICERs for all comparisons were
Table 3 – One-way sensitivity analysis showing the effect
Changes made to Southampto
Statins comparison Cohort of 1000 men, 55–64 years ol
Adjustments to effectiveness of in
utility values discount rates
Remove heart failure
CHD mortality in the post-MI first
CHD mortality in the MI subsequen
CHD mortality in unstable angina
CHD mortality angina
Prevalence of angina and MI†
Utility rates adjusted for age‡
PCI comparison Cohort of 1000 men, 55–64 years ol
All included costs§
Utility values used in health states
Prevalence of angina, MI, and hear
Clopidogrel comparison Cohort of 1000 men and women, 6
MI  NSTEMI
Discount rates 6%  costs, 1.5% 
Utility values used in health states
Prevalence of angina, MI, and hear
CHD, coronary heart disease; MI, myocardial infarction; NSTEMI, non
tion; QALY, quality-adjusted life year.
* Changes made in each comparison adjust the values used in the S
model.
† We calculated percentages using the proportions given. To calcul
angina plus the proportion of unstable angina patients, divided by
[TIA] or stroke patients).
‡ These age-related utilities were multiplied by the health state utili
§ In the base case comparison only the cost of the intervention itself
 Angina, long-term MI, short-term MI, and heart failure; no unstableomparatively close, particularly after input values had been idjusted in the Southampton treatment model. The conclu-
ion for all models compared was that the intervention (in the
valuated patient group) would have been cost effective using
ICE threshold values [4]. These results were consistent with
he existing literature. Mauskopf and colleagues [11] pub-
ished a review of the cost-effectiveness of clopidogrel. Part of
his review covered eight studies based on the Clopidogrel in
nstable Angina to Prevent Recurrent Events trial [12], includ-
ng the York-clopidogrelmodel. All these studies were consid-
red to be within the cost-effectiveness thresholds for their
ountry of analysis. Ward et al [7] carried out a literature re-
iew and identified three UK studies that included statins for
econdary prevention. Reported ICERS ranged from £5291 to
42,483 per life year gained. However, these estimates were
ade using prices obtained while all statins were within
atent and, hence, would overestimate current ICERs. Wailoo
nd colleagues [13] adapted the York-PCI model to use cost
nd treatment delay estimates derived from the National In-
arct Angioplasty Project (NIAP). They found a similar estimate
f the ICER for angioplasty of £4520 per QALY.
The Southampton treatment model used a disease-based
pproach tomodel a wide range of CHD interventions. Each of
he three comparator models was a single technology model
hat evaluated a single intervention or group of closely linked
nterventions. A difficulty faced by the Southampton model
as that the same structure had to be used for a variety of
nterventions. For this reason the model structures used for
e changes made to each variable.
atment model* Cost QALY C/QALY
1900 0.505 3760
ntion, statin cost, 3130 0.711 4400
2050 0.424 4830
tate 1900 0.501 3790
rs health state 1920 0.453 4240
1900 0.523 3630
1930 0.436 4430
1960 0.455 4310
1900 0.407 4670
count rates 3.5% 800 0.065 12,250
740 0.065 11,390
800 0.065 12,280
re 1010 0.082 12,360
years old, 50% of 130 0.013 9930
ts 110 0.016 6690
130 0.014 9280
re 140 0.014 10,320
evationmyocardial infarction; PCI, percutaneous coronary interven-
ampton treatment model to those used in the relevant comparator
e percentage of angina patients, we used the proportion of stable
otal number of patients (not including the transient ischemic attack
give a combined utility value.
changed.
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58 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0or that intervention. In addition, single intervention models
ere more flexible and could answer specific questions. For
xample, the York-PCI model presented scenario analysis
odeling the effect of altering the additional time delay until
ngioplasty as well as differences in the initial length of stay.
hese types of scenario analysis would have been difficult to
eplicate in the Southampton treatment model. The technol-
gymodels are also likely to bemore parsimonious, which has
een identified as a desirable attribute of models [14].
In contrast, the Southampton model could estimate the
omparative cost-effectiveness of different interventions and
he economic impact of policies which would cover many as-
ects of CHD care. Thismay have appeal to decisionmakers as
t would allow the evaluation of a wider range of different
echnologies on a common framework. The Southampton
reatment model incorporated data on the UK prevalence of
HD disease states and annual incidence of new CHD cases;
herefore, it also could address issues of the effect of strategies
n the present and future burdens of CHD. The choice be-
weenmodelswould depend on the question being addressed.
Comparisons required changes to the structure of the
outhampton treatment model. These were greatest for the
omparisons with the York models, which included a two-
tage process where a decision tree fed into a long runMarkov
odel. The York-PCI model included stroke and revascular-
zation, whereas the Southampton model included heart fail-
re but not stroke. These differences could not be addressed
ithout significant structural alterations to the Southampton
odel. For the York-clopidogrel model comparison further
tructural changes were needed. MI can be distinguished (on
he basis of electrocardiograms) into ST elevation MI and
on-ST elevation MI (NSTEMI). Guidelines recommend differ-
nt management for these conditions [15], with clopidogrel
ecommended for NSTEMI patients [16]. The York-clopidogrel
odel included individuals with unstable angina and those
ith NSTEMI. However, the Southampton model did not dis-
inguish between types of MI. Compatibility was achieved by
ssuming that 50% of MI patients in the Southampton model
ere NSTEMI, based on expert opinion.
In addition to structural differences, the present study was
seful in identifying differences in the data used in the various
odels. The Southampton and York-PCI models used a 3.5%
iscount rate for both costs and benefits; the ScHARR-statin
nd York-clopidogrel models used 6% for costs and 1.5% for
enefits. All teams used the rates recommended by NICE at
he time of analysis andwould use themost up-to-date values
n any subsequentmodeling (currently 3.5% for both costs and
enefits). There was a large difference in the cost of drugs in
he two statin models with the value used for the annual cost
f statins in the Southampton model approximately half of
hat in the ScHARR statin model. Again, this reflects the
iming of analysis with the cost being calculated in the
outhampton model after certain statins had come “off
atent.” Costs were also an important difference for the PCI
omparison; again this reflects timing of analysis as the York-
CI model used an earlier cost year (2003–2004 compared to
005–2006). All teamswere clear that they would use themost
p-to-date and appropriate costs available at the time of anal-
sis. cThere were differences in the parameter values used in the
odels where it was harder to reach agreement between
eams on the optimum values to be used. All models used
tility values derived from a variety of sources. The choice of
tility values could not be said to be entirely satisfactory in
ny of themodels. These represent an opportunistic sample of
alues and were derived from different studies; using differ-
nt age groups, proportions of men and women, and disease
everities. The relative values attached to different disease
tates are likely to have distortions and inaccuracies. The
omparison of models shown here has highlighted that utility
alues can lead to differences in model results. We are not
ware of any work that would provide a credible and consis-
ent set of utility values in CHD. This represents an areawhere
etter data are needed to improvemodels, for example, froma
arge-scale survey of people with different CVD conditions us-
ng appropriate methodology and recording relevant individ-
al characteristics such as age, gender, disease, and severity.
t may also be obtainable from a systematic review or a UK
onsensus of experts (both modelers and clinicians).
Another important difference in input values between
odels where no consensus was reached was in the choice
f mortality rates. For CHD-related mortality rates, the
outhampton treatment model used Scottish data [17,18] and
nformation from the Echocardiographic Heart of England
creening Study [19]. The Southampton model adjusted data
o allow for differences in standard mortality rates between
ngland and Wales (combined data) and Scotland. Adjust-
ents were also necessary because these data were col-
ected after the introduction of relevant interventions, such
s statins. The ScHARR-statin and both York models used
he Nottingham Heart Attack Register [20]. These led to dif-
erences in the values used, particularly those for stable
ngina and 1-year post-MI. This is also an area which would
enefit from achieving a consensus on themost appropriate
ata source for UK coronary models. The choice of the op-
imum data set to use would be a complex decision and
hould include the views of both modelers and clinicians as
o which set of values best represents the current experi-
nce of UK individuals with CHD.
We are aware of three similar exercises covering diabe-
es, colorectal cancer screening, and rheumatoid arthritis
odeling. The Mount Hood Challenge [21,22] compared in-
ernational diabetes models by populating parameters us-
ng a common data set. This exercise required prior defini-
ions of disease states and assumptions, and a new data set
o model, and concluded that it was feasible to cross-vali-
ate and explain differences in dissimilar diabetes simula-
ion models using standardized patients. In this example,
ide differences in model results were observed and the
uthors concluded that this demonstrated the need for
ross-validation [21]. They also concluded that performing
ystematic comparisons and validation exercises enabled
he identification of key differences among the models, as
ell as their possible causes and directions for improve-
ent in the future [22]. A similar exercise was carried out in
olorectal cancer where participants used their models to
ddress pre-specified screening scenarios [23]. The authors
oncluded that comparisons can identify critical sources of
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59V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 5 3 - 6 0ariation. They also stated that the next steps to such an
xercise would be modelers and clinicians continuing to
ork together to resolve differences identified. Four models
f rheumatoid arthritis were also compared [24]. This was
argely done from the published articles by comparing
odel descriptions and published sensitivity analysis. The
uthors had electronic access to one model; this was com-
ared to one of the other models by inputting data values
rom a second model. However, this was not done for the
ther two models as these had different structures and the
uthors felt comparisons were not feasible. The authors
ound that output differences depended on structure, as-
umptions, and utilities, and concluded by emphasizing the
eed for transparency in reporting and for a continuing de-
ate on model quality in order to reach consensus on diffi-
ult methodological issues.
These studies show that a number of different approaches
ave been used to compare models. Comparing published re-
ults and sensitivity analyseswould be the simplest approach,
nd would be feasible from public domain information with-
ut requiring access to any of themodels used. Thismethod is
ikely to be limited in its ability to explain the reasons for
ifferences in results. Using a common data set or setting a
eries of scenarios for each model to address would require
he cooperation of all modeling teams involved. However, it
ould give information on how each model is altered with
hanges in inputs and values, and what answers different
odels give to a common question. The current exercise rep-
esents a compromise – it did not require sharing models,
nstead it relied on changing the data input to onemodel only.
his was facilitated by an exchange of information between
odeling teams.
We found the current exercise feasible but demanding.
omparison was aided by the fact that two of three compara-
or models were published as Health Technology Assessment
HTA) monographs [7,9] and these are considerably more de-
ailed thanmost journal articles.Word count limitations often
estrict the level of detailed information possible, requiring
n-depth discussion with the model owner to accurately re-
eat the scenario. In fact, even with these detailed reports,
ooperation between teams was required in terms of answer-
ng specific questions and also supplying further information
ot available from the published data. We believe that mod-
ling articles should include detailed web appendices to aid
eplication and checks of between-model consistency. How-
ver, it may also be desirable to go beyond this and have ac-
epted standards for the reporting of models, similar to those
n existence for clinical trials. This will ensure more consis-
ency in the ways that models are reported and, hence, may
ake comparing models easier.
In the current exercise, comparison was aided as each
odel involved had been constructed to conform to NICE
uidelines for technology appraisals [4]. However, differences
etween models were generated because recommended dis-
ount rates had changed over time. Although changes in
uidelines will be necessary as methodology evolves and cir-
umstances change, it should be recognized that this may
ake comparing models more difficult and recommended
hanges should be very carefully justified. Adhering to guide- aines meant that there were a number of similarities between
odels, for example, in the use of anNHS cost perspective and
cost per QALY approach. This illustrates the value of guide-
ines in promoting consistency in key methods and parame-
ers. However, adherence to guidelines would not help when
here is genuine uncertainty over the best data source to use.
or example, in the current study, it was not clear as to the
est source of data for both utilities and mortality rates.
Checking between-model consistency requires a poten-
ially large investment in researcher time, and it is impor-
ant to consider situations where the exercise would be use-
ul to modelers and decision makers. This is more likely to
e the case where the condition poses a significant burden
nd where considerable uncertainties exist. CHD is a good
xample of this because it imposes a large health [25] and
conomic burden [26], and is a complex condition. Model
omparison will also be indicated if there are large differ-
nces in model results, particularly if results from different
odels cross decision-maker’s thresholds. Here there will
e considerable uncertainty as to the implications of results
o decision making. Checks of between-model consistency
ill also be useful as a development tool for modelers, as
hese can illustrate the model characteristics that are sim-
lar or different to those of existing models. Model compar-
sons were used for this reason in the current exercise as a
ay of both checking and developing the Southampton
odel. However, we feel it is important to remember that
hecks of between-model consistencies can show differ-
nces between models, but they will have limited use in
emonstrating which one is the “best” model. Often there
ill be no clear indication that one data source or method is
etter than another. A check of between-model consistency
annot be used as a substitute for external validation.
onclusion
he exercise indicated that it was feasible, but not straightfor-
ard, to compare models where there are structural differ-
nces between models. A check of between-model consis-
ency was found to be a useful tool for model development
nd aided the development of the Southampton treatment
odel. We also found model comparison to be useful in iden-
ifyingmodel inputs where therewereweaknesses in the data
vailable and, hence, could be useful in prioritizing future re-
earch needs. Organizations responsible for guidelines should
e aware that changes to these guidelines may make it more
ifficult to comparemodels and this should be a consideration
n the decision as to whether to make changes to preferred
ethods. Fuller publication of models, perhaps through de-
ailed web appendices, could facilitate paper-based compari-
ons. A common standard for model reports similar to that
equired for trials would also facilitate the comparison of
odels. A variety of methods to compare models have been
sed in the literature. It is not currently clear as to the relative
trength andweaknesses of differentmethods andmorework
xploring this issue would be useful. This exercise provides a
seful guide to future CHD modelers and policy makers on
reas requiring further exploration.
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